Global  

NIH begins study of remdesivir with anti-inflammatory drug to treat COVID-19

Reuters Friday, 8 May 2020
The National Institutes of Health said on Friday it has started a clinical study to test a combination of Gilead Sciences Inc's antiviral drug remdesivir and anti-inflammatory drug baricitinib in COVID-19 patients.
0
shares
ShareTweetSavePostSend
 
Video credit: CBS Dallas Digital - Published
News video: USC Testing Anti-Inflammatory Drug To Treat COVID-19

USC Testing Anti-Inflammatory Drug To Treat COVID-19 00:32

USC researchers are studying whether the anti-inflammatory drug baricitinib could be used to treat coronavirus patients. Katie Johnston reports.

You Might Like


Related videos from verified sources

Ask Dr. Nandi: COVID-19 Treatment Update: Blood Plasma, Hydroxychloroquine and Rheumatoid Arthritis Drug [Video]

Ask Dr. Nandi: COVID-19 Treatment Update: Blood Plasma, Hydroxychloroquine and Rheumatoid Arthritis Drug

There’s more bad news concerning Hydroxychloroquine, the drug once touted to be “one of the biggest game-changers” for COVID-19. The largest study to date found no real benefits to using this..

Credit: WXYZ Detroit     Duration: 02:55Published
North Texas Coronavirus Patient Goes Home From Hospital 4 Days After Remdesivir Treatment [Video]

North Texas Coronavirus Patient Goes Home From Hospital 4 Days After Remdesivir Treatment

It was last month when 39-year-old Marcus Hawkins started feeling sick. What started with sinus issues progressively got worse.

Credit: CBS 11 Dallas     Duration: 02:20Published
Acute Respiratory Distress In COVID-19 Patients May Be Helped By Arthritis Med [Video]

Acute Respiratory Distress In COVID-19 Patients May Be Helped By Arthritis Med

A new study reveals a drug meant to treat rheumatoid arthritis may be of help to patients struggling to breathe due to the novel coronavirus. According to UPI, Anakinra has been used off-label to..

Credit: Wochit     Duration: 00:35Published

Related news from verified sources

New drug combination being tested to conquer COVID-19

Researchers hope giving Remdesivir along with a powerful anti-inflammatory could be the key to treating the most severe COVID-19 cases.
Science Daily

More Evidence Doesn’t Support Hydroxychloroquine For Patients With COVID-19

The anti-inflammatory drug hydroxychloroquine does not significantly reduce admission to intensive care or death in patients hospitalised with pneumonia due to...
Eurasia Review Also reported by •Science Daily

Antibe Therapeutics expects results from Phase 2B study of pain drug ATB-346 within six weeks

Antibe Therapeutics Inc (CVE:ATE) (OTCQB:ATBPF) has told shareholders that it expects to release topline results from the Phase 2B study of its flagship pain...
Proactive Investors


Tweets about this